MM-121 is a fully human monoclonal antibody that targets ErbB3, while erlotinib (Tarceva) is a small molecule directed at the epidermal growth factor receptor (EGFR).
The study is intended to determine Progression Free Survival (PFS) when combining MM-121 and erlotinib in three distinct metastatic NSCLC patient populations including Group A, Group B and Group C.
The patients in Group A do not have an EGFR activating mutation in their tumors and will be randomized to receive either MM-121 in combination with erlotinib or erlotinib alone.
Group B patients’ tumors have an EGFR activating mutation and will be randomized to receive either MM-121 in combination with erlotinib or erlotinib alone.
Group C that will receive MM-121 in combination with erlotinib, includes patients whose tumors had responded to EGFR targeted therapy and subsequently acquired resistance.